Clinical Trial Update: A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating FOLFOX or FOLFIRI with AG-013736 (cediranib) or bevacizumab in metastatic colorectal cancer after failure of one first-line regimen; th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• AG-013736
• Bevacizumab (bevacizumab)

Snippet

Sponsor: Pfizer | Conditions: Colorectal Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2012-04-20